TITLE: GOUT: A COMPREHENSIVE REVIEW OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT APPROACHES
AUTHOR(S): Nikita G. Tuppekar*, Vaishnavi S. Tuppekar, Kadambari V. Pawar, Sneha M. Kale, Rajani R. Pasale, Ashlesha S. Navale, Ishwari A. Nimbalkar, Tejaswini M. Biraje.
Abstract:
Gout is a common metabolic disorder characterized by hyperuricemia and the deposition of monosodium urate crystals in joints and soft tissues, leading to episodes of acute inflammation and chronic joint damage. It manifests initially as acute gouty arthritis with sudden, severe joint pain and can progress to chronic tophaceous gout and renal complications if left untreated. The pathogenesis involves disruptions in uric acid metabolism, crystal formation, and an intense inflammatory response mediated by the NLRP3 inflammasome and pro-inflammatory cytokines. Diagnosis is based on clinical features, laboratory tests, and imaging modalities. Effective management combines acute symptomatic treatment, long-term urate-lowering therapy, and lifestyle modifications. Early intervention is critical to prevent irreversible joint damage and associated comorbidities, improving patient outcomes and quality of life.
Keywords:
Clogged pores, inflammation, synthetic & herbal treatments, bacterial infection.
Introduction:
Gout is a metabolic disorder where levels of uric acid in the blood are elevated (hyperuricemia), permitting monosodium urate crystals to form and deposit within joints and soft tissues[1]. Usually, this elicits very sudden and severe bouts of joint inflammation and pain, with the affliction of podagra (big toe), although other joints can also be affected [2].
Types of Gout:
Acute Gout: It is an acute attack with sudden pain, swelling, redness, and warm sensation in a single joint, usually the great toe [3]. It is thus called podagra. It commonly happens at night, and can be precipitated by alcohol, trauma, surgery, or excessive consumption of high-purine foods [4]. Intense inflammation occurs because of the immune response to urate crystal deposition in the joint [5]. Without treatment, these attacks can last from several days to weeks and can recur [6].
Chronic Gout: Chronic gout occurs over a while with recurrent acute attacks in the presence of prolonged hyperuricemia [7]. It consists of persistent inflammation of the joints, which may be polyarticular, like knees, elbows, wrists. Chronic gout can produce joint deformity, quite
limiting mobility, and damaging to cartilage and bone. Undoing treatment, this disorder would turn out to be a very disabling one severely affecting the quality of life achievable [8].
Tophaceous Gout: These commonly Tophaceous gout is an advanced form of gout characterized by the formation of tophi, which are large, visible deposits of monosodium urate crystals in soft tissues [9]. develop in the ears, fingers, toes, and around joints. Tophi can become painful,
inflamed, and even ulcerated, sometimes releasing a chalky white substance. This type usually appears after years of uncontrolled gout and signals long-standing, poorly managed hyperuricemia [10].
2. Etiology and Risk Factors of Gout
Primary and Secondary Causes: In the onset of gout, hyperuricemia takes the stage; the serum uric acid level goes above its solubility limit, setting an environment for monosodium urate crystals to stay affixed to joints and tissues [11]. Depending on the cause behind it, gout might be classified as either of two: primary or secondary.
Primary Causes:
Primary gout is caused by inherited or idiopathic abnormalities in purine metabolism [12]. The condition is usually linked to excess production or reduced excretion of uric acid in the absence of any underlying disease [13]. Most cases of primary gout are secondary to renal under-excretion of uric acid [14]. The major etiological factor is inheritance in that it most often runs in families [15]. Defects in relevant enzymes such as HGPRT deficiency in some cases of Lesch-Nyhan syndrome may also be associated with primary hyperuricemia. It
mainly affects adult males and females after menopause [16]. Further, in case there's a sudden increase in serum urate concentration or saturation level in the plasma, tissue, or extracellular fluid, gout nephropathy, another form of renal damage resulting from uric acid crystallization, develops from primary gout [17].
Secondary Causes:
Secondary gout occurs whenever it develops secondary to any disease or by medications that alter the metabolism of uric acid [18]. Chronic kidney disease is a common etiology as it limits the excretion of uric acid by the body [19]. Other secondary etiologies are
hematological malignancies (such as leukemia), psoriasis, or treatments that induce rapid cell turnover resulting in accelerated purine breakdown[20]. Acceptable medications include thiazide-type diuretics, low-dose aspirin, cyclosporine, and chemotherapy agents that
precipitate gout by inhibiting uric acid excretion [21].
Risk Factors:
Genetic Factors:
In other words, a strong genetic predisposition plays a huge role in acquiring gout [22]. Gene variants in SLC2A9, ABCG2, URAT1, and others modify the efficiency of urate transport and kidney functions, thereby causing hyperuricemia [23]. Since genes determine abnormalities in uric acid handling, gout is more common in individuals whose parents suffer from gout [24].
Lifestyle Factors:
The various lifestyle activities greatly determine the onset of gout. Alcohol consumption, especially beer and hard liquor, increases the production of uric acid and decreases its elimination [25]. Being obese gives rise to insulin resistance and decreases kidney function,
both of which contribute to lower levels of uric acid elimination [26]. Lesser physical activity and dehydration on a chronic basis further deteriorate the condition by limiting the kidneys & 39; capacity to eliminate urates [27].
Dietary Factors:
Diet plays a major role in increasing uric acid levels [28]. Foods rich in purines, such as red meat, liver, kidney, shellfish, and anchovies, may cause uric acid to be set at high levels in the blood after digestion [29]. High-fructose corn syrup in soft drinks and processed foods also significantly leads to its elevation [30]. Hence, less consumption of dairy, fruits, and vitamin C are said to be associated with higher risk, as they can drop serum uric acid [31].
Comorbid Conditions:
Several health conditions predispose individuals to gout. Hypertension, type 2 diabetes mellitus, obesity, dyslipidemia, and chronic kidney disease are some of the conditions [32]. These comorbidities may make the kidneys incapable of excreting uric acid efficiently or stimulate the overproduction of uric acid [33]. Metabolic syndrome formation in which some of these conditions coexist is strongly associated with an increase in the risk for gout [34].
References
1. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Advances in therapy. 2015 Jan;32(1):31-41.https://doi.org/10.1007/s12325-014-0175-z
2. SIMKIN PA. The pathogenesis of podagra. Annals of Internal Medicine. 1977 Feb 1;86(2):230-3.https://doi.org/10.7326/0003-4819-86-2-230
3. Wiler JL. Quick Consult: Symptoms: Great Toe Pain and Swelling. Emergency Medicine News. 2011 Dec 1;33(12):6-20.10.1097/01.EEM.0000410111.93592.6e
4. Maher L, Oghene JE, Reginato AM. Crystal-Induced Arthritis. InRheumatology for Primary Care Providers: A Clinical Casebook 2021 Nov 9 (pp. 147-210). Cham: Springer International Publishing.https://doi.org/10.1007/978-3-030-80699-6_7
5. Martinon F. Mechanisms of uric acid crystal‐mediated autoinflammation. Immunological reviews. 2010 Jan;233(1):218-32. https://doi.org/10.1111/j.0105-2896.2009.00860.x
6. Millikan CH, McDowell FH. Treatment of transient ischemic attacks. Stroke. 1978 Jul;9(4):299-308.https://doi.org/10.1161/01.STR.9.4.299
7. Grassi, W., & De Angelis, R. (2011). Clinical features of gout. Reumatismo, 63(4), 238–245. https://doi.org/10.4081/reumatismo.2011.238
8. Frisch, M. B. (2016). Quality of life therapy. In A. M. Wood & J. Johnson (Eds.), The Wiley handbook of positive clinical psychology (pp. 409–425). Wiley. https://doi.org/10.1002/9781118468197.ch27
9. Forbess, L. J., & Fields, T. R. (2012). The broad spectrum of urate crystal deposition: Unusual presentations of gouty tophi. Seminars in Arthritis and Rheumatism, 42(2), 146–154. WB Saunders.https://doi.org/10.1186/s12891-019-2519-y
10. Sharma, P., Singh, P., & Bhinda, A. (2021). Hyperuricemia: A systemic review. World Journal of Pharmaceutical Research, 10(1), 911–922. https://doi.org/10.2165/00003495-200464210-00003
11. Parthasarathy, P., & Vivekanandan, S. (2018). Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: A comprehensive review. Health Information Science and Systems, 6(1), 19.https://doi.org/10.1007/s13755-018-0058-9
12. Cameron, J. S., Moro, F., & Simmonds, H. A. (1993). Gout, uric acid and purine metabolism in paediatric nephrology. Pediatric Nephrology, 7(1), 105–118. https://doi.org/10.1007/BF00861588
13. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. International journal of cardiology. 2016 Jun 15;213:8-14.https://doi.org/10.1016/j.ijcard.2015.08.109
14. Emmerson BT. Gout, uric acid and renal disease. Medical Journal of Australia. 1976 Mar;1(12):403-5.https://doi.org/10.5694/j.1326-5377.1976.tb140703.x
15. Plomin R. The role of inheritance in behavior. Science. 1990 Apr 13;248(4952):183-8.https://doi.org/10.1126/science.2183351
16. Torres, R.J., Puig, J.G. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis 2, 48 (2007). https://doi.org/10.1186/1750-1172-2-48
17. Mei Y, Dong B, Geng Z, Xu L. Excess uric acid induces gouty nephropathy through crystal formation: a review of recent insights. Frontiers in endocrinology. 2022 Jul 14;13:911968.https://doi.org/10.3389/fendo.2022.911968
18. GUTMAN AB. Primary and secondary gout. Annals of internal medicine. 1953 Nov 1;39(5):1062-76.https://doi.org/10.7326/0003-4819-39-5-1062
19. Richard J. Johnson, Takahiko Nakagawa, Diana Jalal, Laura Gabriela Sánchez-Lozada, Duk-Hee Kang, Eberhard Ritz, Uric acid and chronic kidney disease: which is chasing which?, Nephrology Dialysis Transplantation, Volume 28, Issue 9, September 2013, Pages 2221–2228, https://doi.org/10.1093/ndt/gft029
20. Sankar V, Villa A. Hematologic diseases. Burket's Oral Medicine. 2021 Aug 30:627-64.https://doi.org/10.1002/9781119597797.ch17
21. Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, Ferdinandy P, Grove EL, Rocca B, Magavern E, Sulzgruber P. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. European Heart Journal-Cardiovascular Pharmacotherapy. 2024 Apr;10(3):219-44.https://doi.org/10.1093/ehjcvp/pvae013
22. Reginato, A., Mount, D., Yang, I. et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 8, 610–621 (2012). https://doi.org/10.1038/nrrheum.2012.144
23. Adomako EA, Moe OW. Uric acid transport, transporters, and their pharmacological targeting. Acta Physiologica. 2023 Jun;238(2):e13980.https://doi.org/10.1111/apha.13980
24. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine. 2011 Jan 1;78(1):35-40. https://doi.org/10.1016/j.jbspin.2010.02.027
25. Nieradko-Iwanicka B. The role of alcohol consumption in pathogenesis of gout. Critical reviews in food science and nutrition. 2022 Sep 1;62(25):7129-37. https://doi.org/10.1080/10408398.2021.1911928
26. Abate N, Chandalia M, Cabo-Chan Jr AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney international. 2004 Feb 1;65(2):386-92. https://doi.org/10.1111/j.1523-1755.2004.00386.x
27. Johnson RJ, Stenvinkel P, Jensen T, Lanaspa MA, Roncal C, Song Z, Bankir L, Sánchez-Lozada LG. Metabolic and kidney diseases in the setting of climate change, water shortage, and survival factors. Journal of the American Society of Nephrology. 2016 Aug 1;27(8):2247-56.DOI: 10.1681/ASN.2015121314
28. Cheng S, Shan L, You Z, Xia Y, Zhao Y, Zhang H, Zhao Z. Dietary patterns, uric acid levels, and hyperuricemia: a systematic review and meta-analysis. Food & Function. 2023;14(17):7853-68.https://doi.org/10.1039/D3FO02004E
29. Kaneko K, Aoyagi Y, Fukuuchi T, Inazawa K, Yamaoka N. Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biological and Pharmaceutical Bulletin. 2014 May 1;37(5):709-21.https://doi.org/10.1248/bpb.b13-00967
30. Bray GA. Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people. Advances in nutrition. 2013 Mar 1;4(2):220-5. https://doi.org/10.3945/an.112.002816
31. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. The Journal of rheumatology. 2008 Sep 1;35(9):1853-8.https://doi.org/10.1016/j.jbspin.2014.05.007
32. Asghari, K.M., Zahmatyar, M., Seyedi, F. et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC MusculoskeletDisord 25, 1047 (2024). https://doi.org/10.1186/s12891-024-08180-9
33. Dissanayake LV, Spires DR, Palygin O, Staruschenko A. Effects of uric acid dysregulation on the kidney. American Journal of Physiology-Renal Physiology. 2020 May 1;318(5):F1252-7. https://doi.org/10.1152/ajprenal.00066.2020
34. Thottam, G.E., Krasnokutsky, S. & Pillinger, M.H. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep 19, 60 (2017). https://doi.org/10.1007/s11926-017-0688-y
35. Anaizi N. The impact of uric acid on human health: Beyond gout and kidney stones. Ibnosina Journal of Medicine and Biomedical Sciences. 2023 Sep;15(03):110-6.DOI: 10.1055/s-0043-1770929
36. Berens RL, Krug EC, Marr JJ. Purine and pyrimidine metabolism. InBiochemistry and molecular biology of parasites 1995 Jan 1 (pp. 89-117). Academic Press.https://doi.org/10.1016/B978-012473345-9/50007-6
37. Battelli MG, Bortolotti M, Polito L, Bolognesi A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2018 Aug 1;1864(8):2557-65.https://doi.org/10.1016/j.bbadis.2018.05.003
38. Gremels H, Bodo R. The excretion of uric acid by the kidney. Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. 1926 Sep 1;100(703):336-59.https://doi.org/10.1098/rspb.1926.0053
39. Korda ММ, Gozhenko АІ, Popovych IL, Klishch IM, Bombushkar IS, Korda IV, Badiuk NS, Zukow VA, Smagliy VS. Neurotropic, Hormonal and Immunotropic Activity of Uric Acid.https://repository.tdmu.edu.ua//handle/123456789/18234
40. Sorensen LB, Levinson DJ. Origin and extrarenal elimination of uric acid in man. Nephron. 1975 Nov 28;14(1):7-20.https://doi.org/10.1159/000180432
41. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. InSeminars in nephrology 2011 Sep 1 (Vol. 31, No. 5, pp. 447-452). WB Saunders.https://doi.org/10.1016/j.semnephrol.2011.08.009
42. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, Tabah-Fisch I, Keller B, Beaver TM, Nakagawa T, Johnson RJ. Could uric acid have a role in acute renal failure?. Clinical Journal of the American Society of Nephrology. 2007 Jan 1;2(1):16-21.DOI: 10.2215/CJN.00350106
43. Cui Y, An P, Li F, Duan F, Mei Z, Ye Q, Wang G, Zhang H, Luo Y. Strategies to reduce uric acid through gut microbiota intervention. Frontiers in Microbiology. 2025 Aug 29;16:1654152.https://doi.org/10.3389/fmicb.2025.1654152
44. Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C. Physiology of hyperuricemia and urate-lowering treatments. Frontiers in medicine. 2018 May 31;5:160.https://doi.org/10.3389/fmed.2018.00160
45. Dieppe PA, Crocker PR, Corke CF, Doyle DV, Huskisson EC, Willoughby DA. Synovial fluid crystals. QJM: An International Journal of Medicine. 1979 Oct 1;48(4):533-53. https://doi.org/10.1111/j.1532-5415.1980.tb01116.x
46. Gliozzi M, Malara N, Muscoli S, Mollace V. The treatment of hyperuricemia. International journal of cardiology. 2016 Jun 15;213:23-7.https://doi.org/10.1016/j.ijcard.2015.08.087
47. Emmerson, B.T. (1978). Abnormal Urate Excretion Associated with Renal and Systemic Disorders, Drugs, and Toxins. In: Kelley, W.N., Weiner, I.M. (eds) Uric Acid. Handbook of Experimental Pharmacology, vol 51. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66867-8_11
48. Reddy M. To Study the Role of Serum Uric Acid as a Risk Factor in Acute Ischemic Stroke in Navodaya Medical College Hospital & Research Centre, Raichur (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
49. Khalil MI, Salwa M, Sultana S, Al Mamun MA, Barman N, Haque MA. Role of serum uric acid in ischemic stroke: A case-control study in Bangladesh. PLoS One. 2020 Aug 3;15(8):e0236747. doi: 10.1371/journal.pone.0236747.
50. Martinon, F., Pétrilli, V., Mayor, A. et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006). https://doi.org/10.1038/nature04516
51. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Current rheumatology reports. 2014 Feb;16(2):400.https://doi.org/10.1007/s11926-013-0400-9
52. Spitz HO, Steinbrocker O, Schwartz S, Schittone M. Fulminating fatal gout. The American journal of medicine. 1949 Apr 1;6(4):513-21.DOI :10.1016/0002-9343(49)90241-7
53. Golovanova OA. Kinetic Characteristics of Crystallization in a Model Synovial Fluid Solution in the Presence of Organic Impurities. Crystallography Reports. 2024 Jun;69(3):452-8. https://doi.org/10.1134/S1063774523020074
54. Rosenthal AK, Mandel N. Identification of crystals in synovial fluids and joint tissues. Current Rheumatology Reports. 2001 Feb;3(1):11-6. https://doi.org/10.1007/s11926-001-0045-y
55. McCarthy GM, Dunne A. Calcium crystal deposition diseases—beyond gout. Nature Reviews Rheumatology. 2018 Oct;14(10):592-602. https://doi.org/10.1038/s41584-018-0078-5
56. Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae DS. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: a literature review. Hip & pelvis. 2024 Mar 1;36(1):1.doi: 10.5371/hp.2024.36.1.1
57. Yao ST, Cao F, Chen JL, Chen W, Fan RM, Li G, Zeng YC, Jiao S, Xia XP, Han C, Ran QS. NLRP3 is required for complement-mediated caspase-1 and IL-1beta activation in ICH. Journal of Molecular Neuroscience. 2017 Mar;61(3):385-95.https://doi.org/10.1007/s12031-016-0874-9
58. Kim SK. The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout. Journal of rheumatic diseases. 2022 Jul 1;29(3):140-53. DOI: https://doi.org/10.4078/jrd.2022.29.3.140
59. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nature Reviews Rheumatology. 2017 Nov;13(11):63947. https://doi.org/10.1038/nrrheum.2017.155
60. Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae DS. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: a literature review. Hip & pelvis. 2024 Mar 1;36(1):1.doi: 10.5371/hp.2024.36.1.1
61. Pinals RS. Polyarthritis and fever. New England Journal of Medicine. 1994 Mar 17;330(11):769-74. DOI: 10.1056/NEJM199403173301108
62. Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. InSeminars in Arthritis and Rheumatism 2020 Jun 1 (Vol. 50, No. 3, pp. S24-S30). WB Saunders.https://doi.org/10.1016/j.semarthrit.2020.04.010
63. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which?. Nephrology Dialysis Transplantation. 2013 Sep 1;28(9):2221-8.https://doi.org/10.1093/ndt/gft029
64. Russell D. Cluster headache: severity and temporal profiles of attacks and patient activity prior to and during attacks. Cephalalgia. 1981 Dec 1;1(4):209-16.https://doi.org/10.1046/j.1468-2982.1981.0104209.x
65. Yehia SR, Duncan H. Synovial fluid analysis. Clinical Orthopaedics and Related Research®. 1975 Mar 1;107:11-24.https://doi.org/10.1016/j.mpdhp.2017.04.002
66. Ahmad Z, Gupta AK, Sharma R, Bhalla AS, Kumar U, Sreenivas V. Dual energy computed tomography: a novel technique for diagnosis of gout. International Journal of Rheumatic Diseases. 2016 Sep;19(9):887-96. https://doi.org/10.1111/1756-185X.12874
67. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential dangers of serum urate-lowering therapy. The American journal of medicine. 2019 Apr 1;132(4):457-67.https://doi.org/10.1016/j.amjmed.2018.12.010
68. Anaizi N. The impact of uric acid on human health: Beyond gout and kidney stones. Ibnosina Journal of Medicine and Biomedical Sciences. 2023 Sep;15(03):110-6.DOI: 10.1055/s-0043-1770929
69. Cox P, Gupta S, Zhao SS, Hughes DM. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatology international. 2021 Jul;41(7):1209-19. https://doi.org/10.1007/s00296-021-04876-6
70. Malanga GA, Yan N, Stark J. Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgraduate medicine. 2015 Jan 2;127(1):57-65.
71. JOPLIN RJ, BAER GJ. Treatment of Arthritic Joints. Journal of the American Medical Association. 1942 Mar 21;118(12):937-44.doi:10.1001/jama.1942.02830120001001
72. Edelman MJ, Meyers FJ, Siegel D. The utility of follow‐up testing after curative cancer therapy: a critical review and economic analysis. Journal of general internal medicine. 1997 May;12(5):318-31. https://doi.org/10.1046/j.1525-1497.1997.012005318.x
73. Long AN, Dagogo‐Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. The journal of clinical hypertension. 2011 Apr;13(4):244-51. Doi:10.1111/j.1751-7176.2011.00434.x
